N/A N=24 Omega-3 for Peri- and Postmenopausal Depression
Depression
Primary: Change in MADRS Score — 12.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=47 Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Weight Percentile at 3 Months — 33.5; 31.0 Weight Percentile, sex and age adjusted
N/A N=819 Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance
Obstructive Sleep Apnea Syndrome · Restless Leg Syndrome
Primary: Prevalence of Obstructive Sleep Apnea Syndrome in Chinese Elderly — 15 % of participants — p=<0.05
Phase 2 N=47 A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date — 73.9 percentage of participants — p=<0.0001
Phase 2 N=11 Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
Primary: Survival — 75 percentage of participants surviving
Phase 2 N=77 Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Alpha 1-Antitrypsin Deficiency
Primary: The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung — 47.980; 45.477; 45.085; 41.354…
Phase 2 N=42 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
Adenocarcinoma of the Lung · Bronchoalveolar Cell Lung Cancer · Non-small Cell Lung Cancer
Primary: Objective Response Rate With Bortezomib Evaluated by Both RECIST Criteria and Computer-assisted Image Analysis. — 5 percentage of responders
Phase 3 N=1,509 A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
In Vitro Fertilization
Primary: Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate) — 39.0; 38.1 Percentage of participants
Phase 2 N=262 Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
Cervical Intraepithelial Neoplasia
Primary: Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment. — 95; 69; 63; 57 percentage of patients
Phase 3 N=405 Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=<0.0001
Phase 2 N=19 Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Bipolar Disorder · Schizoaffective Disorder · Manic Disorder
Primary: Mania Acute Rating Scale (MACS) — 3.9; 6.4 units on a scale — p=0.22
N/A N=139 NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study
Tooth Hypersensitivity
Primary: Baseline Pre-Prophy Assessment (Tactile Sensitivity) — 10.56; 10.00; 10.98 grams
Phase 2 N=360 Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
Acute Heart Failure
Primary: Change in Cystatin C — .12; .11; .07 mg/L
Phase 3 N=508 LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Breast Neoplasms
Primary: Progression-free Survival (PFS) — 5.49; 5.55 Months — p=0.4224
N/A N=21 Insulin and Polycystic Ovary Syndrome
PCOS
Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min